Biocon Ltd. share price target

ICICI Securities Ltd | Retail Equity Research Revenues declined 6% YoY to | 934 crore (I-direct estimate: | 955 crore) due to sluggish API sales, adverse currency movement, GST impact, fire incident at Syngene and lower licensing income EBITDA margins contracted 595 bps YoY to 20.6% (I-direct estimate: 21.2%) mainly due to commissioning of the Malaysian plant Net profit fell 51% YoY to | 81 crore (I-direct estimate: | 88 crore) due to below expected operational performance, higher depreciation...

Revenue grew by 0.23% to Rs. 927.4 Cr in Q1FY18 when compared to the previous quarter Revenue grew by 0.23% to Rs. 927.4 Cr in Q1FY18 when compared to the previous quarter

USFDA's Advisory Committee (ODAC) unanimously voted 16-0 in favor of approval of Biocon/ Mylan's MYL-1401O, biosimilar Trastuzumab (Herceptin) for all indications. It determined MYL-1401O is highly similar to Herceptin. We believe positive ODAC ruling paves way for the approval in US (albeit GMP..

In a significant development that can be termed as a precursor for biosimilar launch in the US, the USFDA Oncologic Drugs Advisory Committee (ODAC) has strongly recommended approval of Biocon/Mylan's proposed biosimilar Trastuzumab, a biologically similar version of Roche's breast-cancer drug Herceptin. Herceptin is indicated to treat certain HER2-positive breast and gastric cancers. The committee voted 16-0 in support of eligible indications of the reference product. During the discussion, ODAC determined that no clinically meaningful...

Revenue fell by 10.1% to Rs. 919.2 Cr in Q4FY17 when compared to the previous quarter. Also it decreased by 1.53% when compared with Q4FY16.

ICICI Securities Ltd | Retail Equity Research Revenues declined 1.5% YoY to | 931 crore (I-direct estimate: | 1055 crore) due to elongated approval timelines in emerging markets, discontinuance of in-licensed products and fire incident at Syngene EBITDA margins contracted 70 bps YoY to 20.1% (I-direct estimate: 25%) mainly due to higher raw material & employee cost. EBITDA declined 4.8% YoY to | 188 crore (I-direct estimate: | 264 crore) Net profit increased 106% YoY to | 127.5 crore (I-direct estimate:...

Q3FY17 PAT (up 67% YoY) was 21% higher than our estimate due to 2.5x increase in licensing income (directly flows to PBT). While EBITDA margin improved to 25.7% (up 401 bps YoY), margin (ex-licensing) improved slightly (up 93 bps YoY) to 19.5%. Much-awaited Insulin facility in Malaysia is commercial..

Revenue grew by 9.7% to Rs. 1022.5 Cr in Q3FY17 when compared to the previous quarter. Also, it grew by 29.59% when compared with Q3FY16.

ICICI Securities Ltd | Retail Equity Research Revenues grew 29% YoY to | 1044 crore (I-direct estimate: | 996 crore) mainly due to a sharp jump in licensing income and robust growth in biologics. Licensing income increased to | 79 crore from | 32 crore in Q3FY16. Biologics revenues grew 60% to | 120 crore EBITDA margins improved 354 bps YoY to 26.4% (I-direct estimate: 24.2%) mainly due to lower raw material & other expenses. Higher licensing income was also contributed to EBITDA...

ICICI Securities Ltd | Retail Equity Research Revenues grew 19.8% YoY to | 954 crore (I-direct estimate: | 1043 crore) mainly due to higher licensing income & growth in biological business. Biological segment revenues grew 26.3% YoY to | 96 crore (I-direct estimate: | 120 crore) EBITDA margins improved 392 bps YoY to 25.2% (I-direct estimate: 23.9%) due to higher licensing income and lower R&D; expenses...